Expert Interview
Discussing the potential of Amgen's KRAS-G12C- inhibitor, sotorasib, in KRAS G12C-mutated mCRC and the results from the CodeBreak 300 phase III study presented at the 2023 ESMO conference.
Ticker(s): AMGNInstitution: BC Cancer Agency
- Medical Oncologist at the Jack Ady Cancer Program and Associate Clinical Professor of Medicine at the University of Calgary
- Clinical practice includes the full spectrum of solid tumors as well as backup in malignant hematology
- Research interests are team focused and include cost effective diagnostic testing, optimum cancer care follow-up and all aspects of community oncology practice
Could you briefly introduce yourself, your expertise, and describe your current practice setting?
Can you please give an overview of how you manage metastatic colorectal cancer patients and your thoughts on the CodeBreaK 300 trial data presented at ESMO 2023?
How many metastatic colorectal cancer patients do you manage monthly?
- What are the current guidelines and processes for colon cancer screening?
Do you use assays like Shield or Cologuard for screening, and what's your experience with them?
What's your opinion on the effectiveness of general cancer screening tests?
- Could you comment on the estimated annual cases of colorectal cancer in the U.S.?
In your experience, what percentage of metastatic colorectal cancer patients have KRAS mutations?
- Is the KRAS G12C mutation prevalence in metastatic colon cancer patients around 3-4% accurate?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
